Literature DB >> 27095008

Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study.

B Svensson1, Mle Andersson1,2, K Forslind1,3, S Ajeganova4, I Hafström4.   

Abstract

OBJECTIVES: Despite improved treatment strategies for rheumatoid arthritis (RA), some patients do not respond satisfactorily. The aim of this study was to investigate the course and outcome of early RA diagnosed during the 1990s and followed for 8 years with a focus on those who did not respond well to treatment.
METHOD: This study included 640 patients (66% women) who were enrolled in the BARFOT (Better Anti-Rheumatic PharmacOTherapy) RA inception cohort between the years 1993 and 1999. The 28-joint count Disease Activity Score (DAS28) < 2.6 criteria were used to assess remission. Persistent disease (PD) was defined as absence of remission at all predefined follow-up visits at 1, 2, 5, and 8 years. Function was assessed by Health Assessment Questionnaire (HAQ) and Signals of Functional Impairment (SOFI) scores and radiological joint damage by the Sharp/van der Heijde score (SHS).
RESULTS: Of the 640 patients, 214 (37%) had PD (43% of the women and 25% of the men). Over the 8 years of follow-up, patients with PD had significantly worse mean values for patient's global health measured on a visual analogue scale (VAS patGH), VAS pain, HAQ, SOFI, and SHS compared with those in the non-PD group. Multivariate logistic regression analyses revealed that female gender, current smoking, disease activity at baseline, and absence of remission at 6 months independently predicted PD.
CONCLUSIONS: Of the patients who entered the early RA inception cohort, 37% suffered a PD course over 8 years. The consequences of PD with regard to general health, pain, function, and joint damage were considerable. Of note, PD was more common in women than in men.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27095008     DOI: 10.3109/03009742.2016.1147595

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  Smoking and female sex as key risk factors associated with severe arthralgia in acute and chronic phases of Chikungunya virus infection.

Authors:  Ivan Delgado-Enciso; Brenda Paz-Michel; Valery Melnikov; Jose Guzman-Esquivel; Francisco Espinoza-Gomez; Alejandro D Soriano-Hernandez; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Gabriel Ceja-Espiritu; Bertha A Olmedo-Buenrostro; Hector R Galvan-Salazar; Osiris G Delgado-Enciso; Josuel Delgado-Enciso; Uriel A Lopez-Lemus; Daniel A Montes-Galindo
Journal:  Exp Ther Med       Date:  2017-12-21       Impact factor: 2.447

2.  A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance.

Authors:  Ingiäld Hafström; Sofia Ajeganova; Maria LE Andersson; Sidona-Valentina Bala; Stefan Bergman; Ann Bremander; Kristina Forslind; Karina Malm; Björn Svensson
Journal:  Open Access Rheumatol       Date:  2019-09-09

3.  Additive Effects of VDBP and 1,25(OH)2D3 on the Viability and Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts.

Authors:  Yeyong Zhang; Shufeng Li; Feng Zhuo; Hongxing Wang; Xiubin Geng; Bing Xu; Luxu Yin; Huaqiang Sun; Xinfeng Yan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-28       Impact factor: 5.555

4.  Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.

Authors:  Emil Rydell; Kristina Forslind; Jan-Åke Nilsson; Lennart T H Jacobsson; Carl Turesson
Journal:  Arthritis Res Ther       Date:  2018-05-02       Impact factor: 5.156

5.  Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus.

Authors:  R Caporali; A Doria; G F Ferraccioli; P L Meroni; D Zavaglia; F Iannone
Journal:  Biomed Res Int       Date:  2018-09-09       Impact factor: 3.411

6.  Novel Compound Q-1 Alleviates Type II Collagen-Induced Arthritis in Rats through the NF-κB Pathway.

Authors:  Ting Xu; Jia-Chen Guo; Sha-Sha Wu; Yan Wang; Xiao-Long Liu; Hai-Bing Qian
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-30       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.